287 related articles for article (PubMed ID: 33752669)
1. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
[TBL] [Abstract][Full Text] [Related]
2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
3. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
Bielak M; Husmann E; Weyandt N; Haas JP; Hügle B; Horneff G; Neudorf U; Lutz T; Lilienthal E; Kallinich T; Tenbrock K; Berendes R; Niehues T; Wittkowski H; Weißbarth-Riedel E; Heubner G; Oommen P; Klotsche J; Foell D; Lainka E
Pediatr Rheumatol Online J; 2018 Apr; 16(1):22. PubMed ID: 29622022
[TBL] [Abstract][Full Text] [Related]
4. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis.
Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D
Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V; Klein A; Horneff G
Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
[No Abstract] [Full Text] [Related]
6. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
[TBL] [Abstract][Full Text] [Related]
7. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
[TBL] [Abstract][Full Text] [Related]
9. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.
Hinze CH; Holzinger D; Lainka E; Haas JP; Speth F; Kallinich T; Rieber N; Hufnagel M; Jansson AF; Hedrich C; Winowski H; Berger T; Foeldvari I; Ganser G; Hospach A; Huppertz HI; Mönkemöller K; Neudorf U; Weißbarth-Riedel E; Wittkowski H; Horneff G; Foell D;
Pediatr Rheumatol Online J; 2018 Jan; 16(1):7. PubMed ID: 29357887
[TBL] [Abstract][Full Text] [Related]
10. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
Shenoi S; Nanda K; Schulert GS; Bohnsack JF; Cooper AM; Edghill B; Gillispie-Taylor MC; Goldberg B; Halyabar O; Mason TG; Ronis T; Schneider R; Vehe RK; Onel K;
Pediatr Rheumatol Online J; 2019 Jul; 17(1):48. PubMed ID: 31331351
[TBL] [Abstract][Full Text] [Related]
11. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review.
Aguiar CL; Pan N; Adams A; Barinstein L; Lehman TJ
Clin Rheumatol; 2015 Oct; 34(10):1821-4. PubMed ID: 25697878
[TBL] [Abstract][Full Text] [Related]
12. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
13. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
15. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
16. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
[TBL] [Abstract][Full Text] [Related]
17. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
[TBL] [Abstract][Full Text] [Related]
18. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
Hinze T; Kessel C; Hinze CH; Seibert J; Gram H; Foell D
Rheumatology (Oxford); 2021 Nov; 60(11):5165-5174. PubMed ID: 33576397
[TBL] [Abstract][Full Text] [Related]
19. Extreme thrombocytosis in systemic juvenile idiopathic arthritis. A case report.
Iacono A; Sprocati M; Giuliani AL; Di Virgilio F; Borgna-Pignatti C; Maggiore G
Ital J Pediatr; 2019 Jun; 45(1):73. PubMed ID: 31234906
[TBL] [Abstract][Full Text] [Related]
20. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.
Gattorno M; Piccini A; Lasigliè D; Tassi S; Brisca G; Carta S; Delfino L; Ferlito F; Pelagatti MA; Caroli F; Buoncompagni A; Viola S; Loy A; Sironi M; Vecchi A; Ravelli A; Martini A; Rubartelli A
Arthritis Rheum; 2008 May; 58(5):1505-15. PubMed ID: 18438814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]